🚨🚨🚨Remember the extraordinary, sudden eradication of Covid severity in Mexico City following the distribution of medical kits including ivermectin to all outpatients testing positive since December 2020?

Mexico City had promised to publish an observational study of the ivermectin intervention impact.

Here it is and it is a giant one (n=233,849):

"we found a negative and significant effect of the ivermectin kit on the probability of hospitalization.
Depending on subsampling, the effect ranges from 50% to 76% difference in hospitalization odds between treated and untreated patients, statistically significant in all cases"
@jjchamie has usefully aggregated easily readable stats on various subgroups from the already made public data set:

Mexico City data show that it has clobbered Covid-19.

With ivermectin outpatient kits.

Denying the scientific evidence with fallacious arguments to serve competing interests is morally compromised, lethal hypocrisy.

Denying treatment to the sick is a crime against humanity.

• • •

Missing some Tweet in this thread? You can try to force a refresh

Keep Current with Covid19Crusher

Covid19Crusher Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!


Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @Covid19Crusher

28 Apr
Some good results from Famotidine (Pepcid) in tiny (n=20), single-blind, placebo controlled trial of Covid inpatients (6 day discharge vs 9, p=.01).

Not enough to put an end to the data famine on that promising Covid-19 drug.

Read 4 tweets
25 Apr
When the swamped hospitals in Belém, Brazil, had to deny hospitalizations, 210 patient in respiratory failure (32% severe) got treated home with the cocktail:

Prednisolone + enoxaparin + clarithromycin + axetylcefuroxime

Deaths: 0.9%.

A nice video with English subtitles for a bit of context:

HT @HobbesMatraca
More on clarithromycin as the potential macrolide of choice against Covid-19 (1/3):

Read 5 tweets
24 Apr
Another inconclusive, underpowered, aborted outpatients randomized controlled-trial of hydroxychloroquine (n=214 on HCQ, 244 on Kaletra, 227 placebo), with data pointing to efficacy (without statistical significance).

jamanetwork.com/journals/jaman… Image
Do not expect the authors to point out that those hospitalization results are entirely and remarkably consistent with the other 4, all identically underpowered, HCQ outpatient RCTs, homogenously pointing to 30%-ish hospitalization benefit. Image
However, the matter of lack of statistical power is now resolved by the national registry study publish in Iran (n=28,759).

The remarkable match of the HCQ/non-HCQ arms strongly signals quasi-randomization.


⬇️Hospitalization -38%
⬇️Deaths -73%

Read 5 tweets
23 Apr
Pegylated Interferon alpha-2b obtains Emergency Use Authorisation in India in moderate Covid-19 patients.

Phase 3 press release low on detail.

Strong results from interferon lambda here:

Read 4 tweets
18 Apr
High quality, propensity-score matched, observational study of ivermectin prophylaxis in the Dominican Republic (n=713).

The control arm was made of those who refused the treatment and did not take the right decision as IVM was 74% protective.

The cumulative risk curve shows that IVM becomes nearly fully protective after a week, i.e. on the second dose.

None of the treated participants who became Covid positive deteriorated (0/326 vs 3/387)
Very interestingly, a follow up analysis has shown prophylaxis fatigue as a growing numbers failed to maintain the weekly regimen.

In an important dose-dependency evidence, infections picked up immediately.
Read 4 tweets
17 Apr
Brilliant paper on how some antidepressants (here Amitriptyline in vitro and ex vivo) enzymatically block Sars-Cov-2 cell entry to great effect.

With likely variant robustness as a bonus.

A second paper reviewing the same matter with a full FIASMA candidate list.

A simple, accessible FIASMA with data already supporting its efficacy:

the cheap, off-patent anti-histamine hydroxyzine (formerly Atarax)

Read 5 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!